SECURITIES AND EXCHANGE COMMISSION

                        WASHINGTON, D.C.  20549

                               FORM 8-K

                            CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934



Date of Report (Date of earliest event reported)       JANUARY 11, 1996 

                            ENZON, INC.

      (Exact  name  of  registrant  as  specified in its charter)




       DELAWARE                    0-12957              22-237286
   (State or other jurisdiction   (Commission          (IRS Employer
       of incorporation)         File Number)          Identification)



        20 KINGSBRIDGE ROAD,  PISCATAWAY, NEW JERSEY    08854
          (Address of principal executive offices)       (Zip Code)



Registrant's telephone number, including area code    (908) 980-4500




     (Former name or former address, if changed since last report)










ITEM 5.  OTHER EVENTS

          Enzon, Inc. ("Enzon" or the "Company") announced  it has received
two  additional  United  States  patents  for  its hemoglobin-based  oxygen
carrier, PEG-hemoglobin, which has potential application in cancer therapy,
trauma situations and elective surgery.

          PEG-hemoglobin is bovine hemoglobin chemically  modified  by  the
Company's  exclusive  PEG-technology.   The attachment of PEG (polyethylene
glycol) extends the blood circulating life  of  a protein, while decreasing
the patient's natural immune reaction to the protein.

          U.S.  Patent No. 5,478,806, "Enhancement  of  Anti-Tumor  Therapy
with Hemoglobin-Based  Conjugates",  covers  tumor  radiosensitization with
PEG-hemoglobin,  regardless  of  source  of  hemoglobin  or   type  of  PEG
conjugate.  Radiosensitization is the process of delivering oxygen to solid
tumors  to  enhance  response to radiation therapy.  Approximately  800,000
cases of cancer diagnosed  in  the  U.S.  each  year  involve  solid tumors
treated  with  radiation.   In  September  1995, Enzon completed a clinical
trial  with 28 healthy volunteers who received  up  to  45  grams  of  PEG-
hemoglobin  --  which  is  equivalent to 1.5 units of blood and exceeds the
dosage required for radiosensitization.   Enzon has begun recruitment for a
multi-dose,  multi-center  clinical  trial  of   PEG-hemoglobin  in  cancer
patients receiving radiation therapy.

          In the new trial, patients will receive  a  once-a-week  dose  of
PEG-hemoglobin  for  each  five days of radiation treatment during a three-
week therapy program.  The Company  believes  that  a  sufficient amount of
PEG-hemoglobin  will remain in the blood to properly oxygenate  tumors  and
optimize radiation during the five day course of treatment.

          U.S. Patent  No. 5,478,805, "Fractionation of Polyalkylene Oxide-
Conjugated  Hemoglobin  Solutions",   covers  a  method  of  simultaneously
fractionating and purifying PEG-hemoglobin  conjugates.  Enzon has received
other patents on PEG-hemoglobin covering compositions,  methods  of use and
purification and manufacturing processes.



                            SIGNATURES


     Pursuant  to the requirements of the Securities Exchange Act of  1934,

the Registrant has  duly  caused  this report to be signed on its behalf by

the undersigned hereunto duly authorized.




Dated:  April 30, 1996




                                              ENZON, INC.
                                             (Registrant)

                                   By:   /s/KENNETH J. ZUERBLIS
                                         Kenneth J. Zuerblis
                                         Vice President, Finance
                                         and Chief Financial
                                         Officer